Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Aldesleukin (Primary) ; Busulfan (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Dinutuximab (Primary) ; Dinutuximab (Primary) ; Doxorubicin (Primary) ; Etoposide phosphate (Primary) ; Filgrastim (Primary) ; Isotretinoin (Primary) ; Levetiracetam (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Natural killer cell therapy (Primary) ; Sargramostim (Primary) ; Stem cell therapies (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 09 Apr 2024 According to Essentia Pharmaceuticals media release, Renaissance Pharma Ltd has been acquired by Essential Pharma.
- 09 Apr 2024 According to Essentia Pharmaceuticals media release, this trial is approaching five-year OS readouts.
- 11 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.